Deconstructing Pancreatic Adenocarcinoma by Targeting the Conductor, MYC

Isabel A. English, Rosalie C. Sears

Research output: Contribution to journalComment/debate


In this issue of Cancer Discovery, Sodir and colleagues employ a pancreatic ductal adenocarcinoma mouse model with mutant KRAS and inducible MYC to demonstrate that MYC acts as a reversible driver of malignant tumor progression. Abrogation of MYC triggers rapid regression and disassembly of the ensemble tumor through both cancer cell-intrinsic and cancer cell-extrinsic mechanisms, providing a compelling rationale for therapeutic targeting of MYC.See related article by Sodir et al., p. 588.

Original languageEnglish (US)
Pages (from-to)495-497
Number of pages3
JournalCancer discovery
Issue number4
StatePublished - Apr 1 2020


ASJC Scopus subject areas

  • Oncology

Cite this